Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein

Hassine, Ikbel Hadj; Gharbi, Jawhar; Hamrita, Bechr; Almalki, Mohammed A.; Rodrı́guez, José F.; M’hadheb-Gharbi, Manel Ben

doi:10.1007/s11033-020-05333-6

Cited by 16 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the use of whole virus vaccines (live and inactivated) has proven their safety and efficacy against poliovirus [250], it is expensive, slow to develop, lacks flexibility to engineer new epitopes and is limited by the culturability of the target EV. To overcome such limitations, an alternative vaccine strategy has been explored for CVB1, 3 and 4, involving the use of empty VLPs as antigens [251][252][253][254]. Generated from recombinantly expressed viral structural proteins, VLPs resemble the native CVB capsid structure but lack the infectious RNA genome.…”

Section: Antiviral Vaccines and Therapeutics For T1d Preventionmentioning

confidence: 99%

“…Thus, VLP-based vaccines can be manufactured without culturing the virus, are modified rapidly with ease and are not subject to safety concerns associated with live virus vaccines. However, it remains to be determined whether VLP-based vaccines can offer a sufficient level of immunogenicity To overcome such limitations, an alternative vaccine strategy has been explored for CVB1, 3 and 4, involving the use of empty VLPs as antigens [251][252][253][254]. Generated from recombinantly expressed viral structural proteins, VLPs resemble the native CVB capsid structure but lack the infectious RNA genome.…”

Section: Antiviral Vaccines and Therapeutics For T1d Preventionmentioning

confidence: 99%

“…To overcome such limitations, an alternative vaccine strategy has been explored for CVB1, 3 and 4, involving the use of empty VLPs as antigens [ 251 , 252 , 253 , 254 ]. Generated from recombinantly expressed viral structural proteins, VLPs resemble the native CVB capsid structure but lack the infectious RNA genome.…”

Section: Antiviral Vaccines and Therapeutics For T1d Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Viruses and Type 1 Diabetes: From Enteroviruses to the Virome

et al. 2021

View full text Add to dashboard Cite

For over a century, viruses have left a long trail of evidence implicating them as frequent suspects in the development of type 1 diabetes. Through vigorous interrogation of viral infections in individuals with islet autoimmunity and type 1 diabetes using serological and molecular virus detection methods, as well as mechanistic studies of virus-infected human pancreatic β-cells, the prime suspects have been narrowed down to predominantly human enteroviruses. Here, we provide a comprehensive overview of evidence supporting the hypothesised role of enteroviruses in the development of islet autoimmunity and type 1 diabetes. We also discuss concerns over the historical focus and investigation bias toward enteroviruses and summarise current unbiased efforts aimed at characterising the complete population of viruses (the “virome”) contributing early in life to the development of islet autoimmunity and type 1 diabetes. Finally, we review the range of vaccine and antiviral drug candidates currently being evaluated in clinical trials for the prevention and potential treatment of type 1 diabetes.

show abstract

Section: Antiviral Vaccines and Therapeutics For T1d Preventionmentioning

confidence: 99%

Section: Antiviral Vaccines and Therapeutics For T1d Preventionmentioning

confidence: 99%

Section: Antiviral Vaccines and Therapeutics For T1d Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Viruses and Type 1 Diabetes: From Enteroviruses to the Virome

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A subunit vaccine uses one or more purified antigens that can trigger the immune system. 55 It does not introduce the whole pathogen and does not require a safe viral vector. The Heplisav‐B vaccine is an example of an approved subunit vaccine produced by yeast cells.…”

Section: Vaccine Technology Platformsmentioning

confidence: 99%

Covid‐19 vaccines and variants of concern: A review

Hassine

2021

Reviews in Medical Virology

275

178

View full text Add to dashboard Cite

Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid‐19 vaccine candidates based on the original Wuhan‐Hu‐1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid‐19 disease: NVX‐CoV2373 (∼96%), BNT162b2 (∼95%), mRNA‐1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP‐CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%). However, vaccine efficacy (VE) can be jeopardised by the rapid emergence and spread of SARS‐CoV‐2 variants of concern (VOCs) that could escape from neutralising antibodies and/or cell‐mediated immunity. Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines. Although many Covid‐19 vaccines have been developed, additional effective vaccines are still needed to meet the global demand. Promising Covid‐19 vaccines such as WIBP‐CorV, AD5‐nCOV, ZyCoV‐D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS‐CoV‐2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid‐19 vaccination and introduces some promising Covid‐19 vaccine candidates.

show abstract

“…Although the use of whole virus vaccines (live and inactivated) have proven their safety and efficacy against poliovirus [246], it is expensive, slow to develop, lacks flexibility to engineer new epitopes and limited by the culturability of the target EV. To overcome such limitations, an alternative vaccine strategy has been explored for CVB1, 3 and 4, involving the use of empty VLPs as antigens [247][248][249][250]. Generated from recombinantly expressed viral structural proteins, VLPs resemble the native CVB capsid structure but lack the infectious RNA genome.…”

Section: Antiviral Vaccines and Therapeutics For T1d Preventionmentioning

confidence: 99%

Viruses and Type 1 Diabetes: From Enteroviruses to the Virome

Isaacs¹,

Foskett²,

Maxwell³

et al. 2021

Preprint

View full text Add to dashboard Cite

For over a century, viruses have left a long trail of evidence implicating them as frequent suspects in the development of type 1 diabetes. Through vigorous interrogation of viral infections in individuals with islet autoimmunity and type 1 diabetes using serological and molecular virus detection methods, and mechanistic studies of virus infected human pancreatic β-cells, the prime suspects have been narrowed down to predominantly human enteroviruses. Here we provide a comprehensive overview of evidence supporting the hypothesised role of enteroviruses in the development of islet autoimmunity and type 1 diabetes. We also discuss concerns over the historical focus and investigation bias toward enteroviruses, and summarise current unbiased efforts aimed at characterising the complete population of viruses (the “virome”) contributing early in life to the development of islet autoimmunity and type 1 diabetes. Finally, we review the range of vaccine and antiviral drug candidates currently being evaluated in clinical trials for the prevention and potential treatment of type 1 diabetes.

show abstract

Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein

Cited by 16 publications

References 33 publications

Viruses and Type 1 Diabetes: From Enteroviruses to the Virome

Viruses and Type 1 Diabetes: From Enteroviruses to the Virome

Covid‐19 vaccines and variants of concern: A review

Viruses and Type 1 Diabetes: From Enteroviruses to the Virome

Contact Info

Product

Resources

About